Certara (NASDAQ:CERT) Shares Up 10.4% - What's Next?

Certara, Inc. (NASDAQ:CERT - Get Free Report)'s share price was up 10.4% during mid-day trading on Wednesday . The company traded as high as $11.86 and last traded at $11.86. Approximately 208,804 shares were traded during trading, a decline of 74% from the average daily volume of 795,817 shares. The stock had previously closed at $10.74.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. UBS Group raised shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target for the company in a report on Friday, September 27th. Barclays reduced their target price on Certara from $14.00 to $12.00 and set an "equal weight" rating for the company in a research note on Thursday, November 7th. Finally, Robert W. Baird dropped their price target on Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a research note on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Certara has an average rating of "Hold" and a consensus price target of $15.92.

Certara Price Performance

The firm has a market cap of $1.93 billion, a PE ratio of -59.80, a price-to-earnings-growth ratio of 5.86 and a beta of 1.52. The stock has a 50 day simple moving average of $10.86 and a two-hundred day simple moving average of $11.95. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $94.80 million during the quarter, compared to analysts' expectations of $95.51 million. During the same period last year, the business earned $0.06 earnings per share. Certara's quarterly revenue was up 10.7% on a year-over-year basis. Sell-side analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Institutional Trading of Certara

A number of hedge funds have recently added to or reduced their stakes in the company. Choreo LLC acquired a new position in shares of Certara in the second quarter worth about $348,000. Oppenheimer Asset Management Inc. raised its holdings in Certara by 45.7% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 197,724 shares of the company's stock worth $2,738,000 after purchasing an additional 61,980 shares during the period. Envestnet Asset Management Inc. boosted its position in Certara by 8.2% during the second quarter. Envestnet Asset Management Inc. now owns 573,660 shares of the company's stock worth $7,945,000 after purchasing an additional 43,403 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Certara by 9.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,773,892 shares of the company's stock valued at $38,418,000 after purchasing an additional 248,448 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Certara by 9.7% in the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company's stock valued at $42,643,000 after purchasing an additional 273,095 shares during the period. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.